Botulinum toxin type A injection of the prostate causes relaxation and cellular apoptosis and by this way will relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia.
ID
Bron
Verkorte titel
Aandoening
Benign prostatic hyperplasia
Ondersteuning
The Netherlands
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Symptom relief according to the International Prostatic Symptom Score(IPSS)
Achtergrond van het onderzoek
Rationale:
The standard treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, not responding to medication, is transurethral prostatic resection. This is an invasive procedure requiring general or regional anestesia. Intraprostatic injection of Botox causes relaxation of smooth muscle tissue and causes cellular apoptosis. Therefore it is possibly effective for treatment of benign prostatic hyperplasia. Transrectal prostatic injection is minimally invasive and can be performed without anestesia in the outpatient clinic.
Objective:
To determine the subjective effect on lower urinary tract symptoms and to determine objective urodynamic and histologic changes after intraprostatic botulinum toxin injection.
Study design:
Prospective.
Study population:
Male patients with lower urinary tract symptoms due to benign prostatic hyperplasia, not responding to medication.
Intervention:
Transrectal injection of botulinum toxin into the prostate.
Main study parameters/endpoints:
Symptom relief (IPSS).
Urodynamic obstruction (according to Schafer)
Post void residual
Decrease of prostate volume
Histologic changes after 1 month.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
At least 8 visits to the outpatient clinic are necessary. Four urodynamic studies will be performed (in total 4 hours). Patients will be asked to fill out questionnaires and voiding diaries with every visit.
There is a risk for prostatitis and a risk for hemorrage due to the prostatic biopsy and after the intraprostatic injection. Furthermore there is a risk for side effects of the botulinum toxin like allergy (infrequently), aritmia and respiratory problems in case of overdose.
Doel van het onderzoek
Botulinum toxin type A injection of the prostate causes relaxation and cellular apoptosis and by this way will relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Onderzoeksproduct en/of interventie
Transrectal intraprostatic injection with botulinum toxin type A
Publiek
P.O. Box 85500
L.M.O. Kort, de
Utrecht 3508 GA
The Netherlands
+31 (0)30 2508079
l.m.o.dekort@umcutrecht.nl
Wetenschappelijk
P.O. Box 85500
L.M.O. Kort, de
Utrecht 3508 GA
The Netherlands
+31 (0)30 2508079
l.m.o.dekort@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Age > 55
2. Signed informed consent
3. LUTS with IPSS (international prostatic symptom score)
> 7
4. Insufficient respons to oral medication
5. Prostatic volume 30-50 ml
6. Urodynamic infravesical obstruction > grade II according to Schafer
7. Willing and able to fill out questionnaires and voiding diaries
8. Willing and able to attend proposed investigations
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Neuropathic bladder dysfunction
2. Prostatic carcinoma
3. Coagulation disorder
4. Urinary tract infection
5. Bladder calculus
6. Postrenal renal insufficiency
7. Myopathic disorder
8. Anatomical defects preventing transrectal approach
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL739 |
NTR-old | NTR749 |
Ander register | : N/A |
ISRCTN | ISRCTN42633050 |